Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22907245 | 0.84 | MAPT (0.50) | MAPTACHEKIF11ALOX5APFEN1 | |
| SCHEMBL20133146 | 0.83 | MAPT (0.53) | MAPTACHEKIF11 | |
| SCHEMBL22906814 | 0.80 | MAPT (0.60) | MAPTACHEKIF11BRD4BRD2 | |
| SCHEMBL27098111 | 0.78 | MAPT (0.64) | MAPTACHEKIF11 | |
| SCHEMBL27098110 | 0.77 | MAPT (0.48) | MAPTACHEKIF11 | |
| SCHEMBL17997396 | 0.75 | MAPT (0.63) | MAPTACHEKIF11TLR9TLR8 | |
| SCHEMBL22906721 | 0.74 | MAPT (0.66) | MAPTACHEKIF11 | |
| SCHEMBL20233712 | 0.72 | MAPT (0.50) | MAPTACHEKIF11TLR8TLR7 | |
| Flortaucipir SCHEMBL29439901 | 0.71 | MAPT (0.77) | MAPTACHEKIF11 | |
| Flortaucipir SCHEMBL29548430 | 0.71 | MAPT (0.77) | MAPTACHEKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | MAPT 5/4885ACHE 3345/4885KIF11 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.